Experimental HIV vaccine breakthrough

A new, experimental vaccine has been created that could reduce the chances of being infected by HIV.

In the world's biggest Aids trial, the vaccine has been shown to decrease the likelihood of infection by more than 31 per cent.

Two vaccines, ALVAC and AidsVAX, were used in combination and tested on more than 16,000 volunteers to produce the results.

The study, which was conducted by the Thailand Ministry of Public Health, has been hailed as a major breakthrough by various international health groups.

A joint statement from the World Health Organisation (WHO) and UNAIDS welcomed the news but called for caution.

The groups noted: "The study results, representing a significant scientific advance, are the first demonstration that a vaccine can prevent HIV infection in a general adult population and are of great importance.

"Until a highly effective HIV vaccine becomes available UNAIDS and WHO underline the importance of effective and proven HIV prevention methods for all people."

The research was sponsored by the US National Institute for Allergy and Infectious Diseases and the US Army Medical Research and Materiel Command, Department of Defence.

News brought to you by Global Health TV, connecting health communities